Researchers at the University of Southern California have identified a potential new approach to combat Alzheimer’s disease by targeting an enzyme that drives harmful brain inflammation, particularly in people carrying the high-risk APOE4 gene variant. The findings, published in recent studies, focus on cytosolic phospholipase A2 (cPLA2), an enzyme that appears to fuel destructive inflammatory processes while remaining essential for normal brain function.
APOE4 carriers face heightened Alzheimer’s risk across populations
Percentage of population carrying APOE4 variant by region, 2024 data
Source: Global genetic studies, Nature Genetics | Georgian Medical Journal News
Targeting inflammation without disrupting essential brain functions
The USC research team, led by investigators at the Keck School of Medicine, has developed potential drug compounds that selectively inhibit the harmful effects of cPLA2 while preserving its necessary functions. According to the published research, this enzyme plays a dual role in brain health, making it a challenging but promising therapeutic target.
The study builds on previous work showing that APOE4 carriers experience more severe neuroinflammation compared to those with other APOE variants. The National Institute on Aging has long recognized APOE4 as the strongest genetic risk factor for late-onset Alzheimer’s disease, affecting approximately one in four people globally.
Enzyme pathway offers precision medicine opportunity
The cPLA2 enzyme regulates the production of inflammatory molecules called eicosanoids, which can either promote harmful inflammation or support brain cell repair depending on the specific pathway activated. The USC researchers found that their experimental compounds could redirect this enzyme’s activity away from destructive processes while maintaining protective functions.
This selective approach represents a significant advancement over broader anti-inflammatory strategies that have failed in previous Alzheimer’s trials. The World Health Organization estimates that 55 million people worldwide live with dementia, with Alzheimer’s disease contributing to 60-70% of cases.
Genetic risk factor drives therapeutic focus
APOE4 carriers face a two to three-fold increased risk of developing Alzheimer’s disease compared to those with the more common APOE3 variant. Recent studies published in major neuroscience journals have shown that this genetic variant triggers excessive microglial activation, leading to chronic brain inflammation that damages neurons over time.
The USC findings suggest that targeting cPLA2 could be particularly beneficial for this high-risk population. For broader context on emerging Alzheimer’s research, multiple laboratories worldwide are investigating how genetic risk factors influence therapeutic responses.
Clinical translation and future research directions
The research team is now working to optimize their lead compounds for potential clinical testing. According to the study authors, the next phase will involve extensive safety testing and refinement of the drug candidates to ensure they can cross the blood-brain barrier effectively while minimizing side effects.
The approach aligns with growing interest in precision medicine for neurodegenerative diseases. The FDA has increasingly emphasized the need for treatments tailored to specific genetic risk profiles, particularly given the limited success of previous one-size-fits-all approaches to Alzheimer’s therapy.
The selective inhibition of cPLA2’s harmful pathways while preserving its essential functions represents a promising new direction for Alzheimer’s treatment, particularly for APOE4 carriers who experience heightened neuroinflammation
— USC Keck School of Medicine research team (ScienceDaily, 2026)
Key takeaways
- USC researchers identified cPLA2 enzyme as a dual-function target that could reduce harmful brain inflammation while preserving essential cellular processes
- APOE4 gene carriers, representing 25% of the global population, may benefit most from this targeted approach due to their heightened inflammatory responses
- The selective inhibition strategy offers advantages over previous broad anti-inflammatory approaches that disrupted both harmful and protective immune responses
- Clinical testing of optimized compounds is planned, focusing on blood-brain barrier penetration and safety profiles
Frequently asked questions
How does the APOE4 gene increase Alzheimer’s risk?
The APOE4 variant triggers excessive microglial activation in the brain, leading to chronic inflammation that damages neurons. Carriers face 2-3 times higher risk compared to those with other APOE variants.
What makes targeting cPLA2 different from previous approaches?
Unlike broad anti-inflammatory drugs that failed in trials, this approach selectively blocks harmful inflammatory pathways while preserving the enzyme’s essential functions for normal brain activity. This precision could avoid the side effects that derailed earlier treatments.
When might these treatments become available to patients?
The compounds are still in early research phases requiring safety testing and optimization. Clinical trials would need to demonstrate both safety and efficacy before any potential FDA approval, a process typically taking several years.
The USC findings add to a growing body of research suggesting that precision medicine approaches targeting specific genetic risk factors may offer the best path forward for Alzheimer’s treatment. As researchers continue to unravel the complex relationship between genetics, inflammation, and neurodegeneration, targeted therapies like cPLA2 inhibition represent a shift toward more personalized and potentially effective interventions for this devastating disease.
Source: USC scientists discover a hidden Alzheimer’s trigger and a possible way to shut it down
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
